QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Tixagevimab and Cilgavimab—Classification, History, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tixagevimab and Cilgavimab: Classification, History, Mechanism, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which record would be most complete for a historical breakthrough-infection case?

Both antibody doses and dates, indication, immune status, vaccination and prior infection, infection timing and test, severity, outcome and variant context Only the date of the positive test and the product brand Only the patient's vaccination history and current symptoms Only the viral sequence, without exposure or clinical information

Question 2 of 10 Which information is most important for distinguishing possible variant escape from waning antibody exposure in a breakthrough infection?

The dosing date, infection timing and contemporaneous lineage or variant-susceptibility information The patient's sex alone The product's brand name without the administration date The number of adverse-event reports received during the same month

Question 3 of 10 Which sequence correctly distinguishes the three evidence levels used to evaluate variant-related loss of activity?

Genotypic evidence identifies spike substitutions, phenotypic evidence measures laboratory neutralisation, and clinical evidence evaluates patient outcomes Genotypic evidence measures hospitalisation, phenotypic evidence identifies patient comorbidities, and clinical evidence sequences viral genomes Genotypic evidence establishes causality, phenotypic evidence proves population protection, and clinical evidence is limited to in vitro testing Genotypic, phenotypic and clinical evidence are interchangeable terms for the same laboratory result

Question 4 of 10 For pharmacovigilance exposure records, how should tixagevimab and cilgavimab generally be represented?

As two active substances administered together, with their respective doses and exposure details preserved As two interchangeable names for one active substance As a vaccine exposure because both antibodies provide immune protection As an unspecified biological product because antibody identity is not relevant

Question 5 of 10 Which statement most accurately describes the U.S. regulatory lifecycle discussed in the article?

The EUA became unavailable for use when non-susceptible variants predominated, and it was formally revoked later The EUA was withdrawn solely because of a confirmed fatal cardiovascular toxicity The EUA remained continuously available in all U.S. regions until the EU marketing authorisation was withdrawn The EUA was converted into a permanent marketing authorisation after variant surveillance

Question 6 of 10 Why is COVID-19 infection an important competing factor in assessment of thromboembolic or cardiovascular events?

COVID-19 itself can be prothrombotic and can precipitate cardiovascular complications COVID-19 prevents all adverse drug reactions from occurring COVID-19 changes the antibody product into a vaccine COVID-19 makes event timing clinically irrelevant

Question 7 of 10 A patient develops COVID-19 after correctly administered prophylaxis during a period when a reduced-susceptibility lineage predominated. Which conclusion is most scientifically appropriate initially?

Variant escape is a plausible contributor, but timing, host factors, exposure pressure and clinical data must also be assessed The event proves an administration error occurred The event proves that the antibodies caused the infection The event can be excluded from pharmacovigilance because breakthrough infection is expected with passive immunity

Question 8 of 10 Which statement correctly distinguishes passive antibody prophylaxis from vaccination?

Passive prophylaxis supplies exogenous antibodies, whereas vaccination is intended to induce an adaptive immune response and memory Passive prophylaxis and vaccination are pharmacologically interchangeable exposures Passive prophylaxis permanently replaces the need for vaccination Vaccination supplies preformed antibodies but does not engage the recipient's immune system

Question 9 of 10 Why should an increase in reported breakthrough infections not automatically be interpreted as a new product defect?

Reporting frequency can be affected by variant prevalence, community transmission, testing, follow-up and reporting behaviour Breakthrough infections are never relevant to effectiveness surveillance Spontaneous reports always provide a complete denominator for exposed patients A product defect can only be identified through administration-site reactions

Question 10 of 10 Which statement best explains why the product's mechanism is described as sequence-dependent?

Changes in spike sequence can alter antibody binding and neutralisation even when the manufactured product is unchanged The antibodies only work when their amino acid sequences change during treatment The mechanism depends solely on the patient's vaccination history The antibodies become active only after the virus has replicated inside host cells

Knowledge Assessment: Tixagevimab and Cilgavimab—Classification, History, Mechanism, Safety and Pharmacovigilance

Cookie Settings